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Abstract
Anti-beta-2-glycoprotein 1 (anti-b2GP1) antibodies are associated with increased thrombotic risk in patients with autoimmune
disease. There is conflicting evidence on the effects of anti-b2GP1 antibodies on platelets, with both enhanced and inhibited
aggregation previously reported. However, previous studies did not include isotype antibodies to ensure the observed effects
were due to anti-b2GP1 antibodies. The aims of this study were to (1) investigate the effects of anti-b2GP1 antibodies on collagen-
induced platelet aggregation in parallel with negative control (buffer normal saline) and isotype control antibodies and (2)
determine the lupus anticoagulant (LA) activity of anti-b2GP1 antibodies used. Three animal-derived anti-human-b2GP1 anti-
bodies (1.25, 2.5, and 5 mg/mL) incubated with healthy platelet-rich plasma were activated by collagen (2.5 mg/mL). Each
anti-b2GP1 antibody demonstrated the inhibition of aggregation compared to negative control, but not to isotype control.
No anti-b2GP1 antibody demonstrated LA activity, suggesting they were probably nonpathological. This study highlights
both negative and isotype control markers are important to validate the effects of anti-b2GP1 antibodies. Assays to measure
anti-domain I-b2GP1 antibodies are recommended to be used in conjunction with functional measures to further investigate the
effects of anti-b2GP1 antibodies.
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Introduction
Anti-beta-2-glycoprotein 1 (anti-b2GP1) antibodies are a type
of antiphospholipid antibody that include a group of heteroge-
neous immunoglobulins (Igs) such as anticardiolipin antibodies
and lupus anticoagulants (LAs).1-3 The presence of anti-b2GP1
antibodies is associated with an increased risk of thrombosis
and/or pregnancy-related complications in patients with auto-
immune conditions, for example, antiphospholipid syndrome
(APS) and systemic lupus erythematosus (SLE). The risks are
even higher in patients with persistently high titers of antibo-
dies and/or positivity for LA activity,4-6 although the precise
mechanism(s) remain to be determined.
Anti-b2GP1 antibodies have been suggested to activate pla-
telets in the presence of b2GP1 via various platelet membrane
receptors, including apolipoprotein E receptor 20 (apoER20),7
glycoprotein Iba (GPIba),8 and the Fc Receptor for IgG,
(FcgRIIa).9 However, there are conflicting reports on the effects
of anti-b2GP1 antibodies on platelet activation and function
using adenosine diphosphate (ADP) and collagen as agonists
in in vitro systems. Both murine monoclonal10 and purified
human anti-b2GP1 antibodies from patients with SLE
1 have
been demonstrated to enhance ADP-induced platelet aggrega-
tion, suggesting a prothrombotic role for anti-b2GP1 antibo-
dies. In contrast, affinity-purified rabbit anti-b2GP1
antibodies significantly inhibited ADP-induced platelet aggre-
gation, in a concentration-dependent manner.1,3 Furthermore,
anti-b2GP1 IgG antibodies in serum from patients with APS
have also demonstrated the inhibition of ADP-induced in vitro
platelet aggregation.11 Using collagen as an agonist in vitro
platelet aggregation was not affected by human serum contain-
ing anti-b2GP1 IgG antibodies
11 but enhanced by rabbit-
derived anti-b2GP1 IgG antibodies.
3 These discrepant results
may be due to the heterogeneous properties of anti-b2GP1
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antibodies, varying avidity, and/or different binding
specificities.
Previous studies investigating the effects of anti-b2GP1 anti-
bodies on platelets1,3,11 have not reported isotype controls used
in parallel to ensure that the inhibitory or pro-aggregatory
effects were due to the antibodies. Furthermore, they did not
determine whether the anti-b2GP1 antibodies demonstrated LA
activity, an established laboratory marker associated with a
higher risk of thrombosis in patients with APS and SLE.4,5,12
The aims of this study were to therefore (1) investigate the
effects of 3 anti-b2GP1 antibodies (and paired isotype control
antibodies) on collagen-induced in vitro platelet aggregation
and (2) determine the LA activity of anti-b2GP1 antibodies.
Methods
Ethics
This study was approved by the Tasmanian Health and Medical
Human Research Ethics Committee (Reference number
H0015749). All participants completed an informed written
consent prior to taking part in the study.
Participants
Healthy donors (n = 24; age, mean + SD = 30 + 10 years)
without any known hemostatic abnormality were recruited for
the study. Participants avoided aspirin and other antiplatelet
medications for 10 days prior to blood collection. They also
avoided food and beverage known to affect platelet function,
for example, garlic, coffee, and alcohol13,14 for at least 1 day
before blood donation.
Antibodies
Commercially available animal-derived IgG antibodies were
used in this study (Table 1). Anti-human-b2GP1 IgG antibodies
used included goat polyclonal (Bethyl Laboratories Inc, Mon-
tgomery, Texas), rabbit polyclonal (Hyphen-BioMed,
Neuville-sur-Oise, France), and rabbit monoclonal (Abcam,
Cambridge, United Kingdom) antibodies. Isotype control IgG
antibodies including goat polyclonal (Bethyl Laboratories Inc),
rabbit polyclonal (Thermo Scientific, Waltham, Massachu-
setts), and rabbit monoclonal (Abcam) antibodies, respectively,
were used in parallel.
Platelet Aggregation
Whole blood samples from healthy donors were collected into
3.8% sodium citrate vacutainer (Vacuette, Greiner Bio-One,
Kremsmünster) with minimal stasis and centrifuged at 150g for
10 minutes at room temperature (RT). After separating platelet-
rich plasma (PRP), the remaining sample was centrifuged at
2000g for 20 minutes at RT to collect platelet-poor plasma
(PPP). For all tests, the platelet count of PRP was adjusted to
250  109/L using PPP from the same donor (measured by
Sysmex XS 1000i; Sysmex, Lincolnshire, Illinois). Experimen-
tal testing was completed within 3 hours of blood collection.
Platelet aggregation was performed using a 4-channel
AggRAM module light transmission aggregometer (Helena
Laboratories, Beaumont, Texas). Aggregation was induced
by 2.5 mg/mL type I equine tendon collagen (25 mL; Helena
Laboratories). Two hundred microliters of PRP was first incu-
bated with 25 mL of commercially available anti-b2GP1 anti-
body or isotype control antibody (final concentrations 5, 2.5,
and 1.25 mg/mL) for 10 minutes at 37C prior to activation by
collagen. Each concentration of antibody was tested in tripli-
cate (PRP + antibody), and a baseline control (PRP + buffer
normal saline, pH 7.1) was included in each run (4 channels: 3
tests + 1 control). Each experiment was repeated using PRP
from 4 different healthy donors. Aggregation software
(HemoRAM 1.1.0; Helena Laboratories) was used to generate
aggregation parameters including percentage maximum aggre-
gation (%MAX), percentage area under curve (%AUC), and
lag time. Results for baseline control were normalized to 0.
Differences between the results from antibodies and baseline
were then determined.
Lupus Anticoagulant Activity
STA-Coag lyophilized control citrated normal human plasma
(NP; Diagnostica Stago, Paris, France) was reconstituted with
distilled water and allowed to stand at RT for 30 minutes before
testing. The LA 1 screening and LA 2 confirmation reagents
(Siemens Healthcare Pty Ltd, Victoria, Australia) were recon-
stituted with distilled water, left at RT for 15 minutes, and then
prewarmed at 37C prior to testing. The LA testing was per-
formed according to the manufacturer’s instructions (Siemens
Healthcare Pty Ltd). Briefly, NP was incubated for 10 minutes
with different commercially available anti-b2GP1 antibodies
(final concentrations 5, 2.5, and 1.25 mg/mL). Siemens LA 1
Table 1. Commercially Available IgG Antibodies Used in the Current Study.
Antibody Host Type Specificity Entrez Gene ID Company Catalog Number
Goat Polyclonal Human albumin 213 Bethyl Laboratories Inc A80-129
Goat Polyclonal Full length Human b2GP1 350 Bethyl Laboratories Inc A80-142A
Rabbit Polyclonal Non-specific N/A Thermo Scientific 02-6102
Rabbit Polyclonal Full length Human b2GP1 350 Hyphen-BioMed PA200A
Rabbit Monoclonal Non-specific N/A Abcam Ab125938
Rabbit Monoclonal Full length Human b2GP1 350 Abcam Ab108348
Abbreviations: b2GP1, beta-2 glycoprotein 1; IgG, immunoglobulin G.
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screening reagent (100 mL) containing Russell’s viper venom
and phospholipids was added to 100 mL of plasma spiked with
antibodies. Antibody-free NP and high and low LA controls
(100 mL) were also assessed. All clotting times were measured
using a STart coagulation analyzer (Diagnostica Stago, Paris)
in triplicate. Samples with a “screen” (S) clotting time greater
than 44 seconds were retested with LA 2 confirmation reagent
(containing higher amounts of phospholipid) to obtain a
“confirm” (C) clotting time. The normal ratio of S/C was 0.8
to 1.2. The ratios for weak, moderate, and strong LA activities
are 1.2 to 1.5, 1.5 to 2.0, and greater than 2, respectively.
Statistical Analysis
All figures were constructed using GraphPad Prism 7 (GraphPad
Software, Inc, La Jolla, California), with platelet aggregation
parameters (%MAX, %AUC, and lag time) expressed as the
mean of difference from baseline (normal buffered saline) +
standard error of the mean. Data were analyzed using mixed-
effects general linear modeling adjusted for repeated measures
(STATA version 14; StataCorp, College Station, Texas). Results
were tested for assumptions of linear regression. If violated, data
were analyzed again with repeated-measures ordinal logistic
regression. All P values were adjusted using Holm post hoc test.
P values less than .05 were considered as statistically significant.
Data from anti-b2GP1 antibodies were first compared against
baseline. If statistically significant, anti-b2GP1 antibodies results
were compared to their isotype control antibody to ensure those
effects were specific for anti-b2GP1 antibodies.
Results
Effects of Goat Polyclonal Anti-b2GP1 IgG Antibodies on
2.5 mg/mL Collagen-Induced Platelet Aggregation Against
Baseline and Isotype Control Antibodies
At all concentrations (1.25, 2.5, and 5 mg/mL) tested, goat
polyclonal anti-b2GP1 antibodies inhibited 2.5 mg/mL
collagen-induced platelet aggregation (%MAX and %AUC)
compared to baseline control (Figure 1A, B). Stronger inhibi-
tion of aggregation was demonstrated with increasing concen-
trations of anti-b2GP1 antibodies (eg, %MAX for 1.25, 2.5, and
5 mg/mL was 4.98% + 0.99%, P < .01; 5.81% + 1.00%,
P < .01; and 6.94% + 1.01%, P < .01, respectively). The
effects of anti-b2GP1 antibodies on lag time were the same as
baseline control (Figure 1C). Although goat polyclonal anti-
b2GP1 antibodies showed inhibitory effects compared to
baseline, these were not significantly different to the isotype
control antibodies (Figure 1A to C).
Effects of Rabbit Polyclonal Anti-b2GP1 IgG Antibodies on
2.5 mg/mL Collagen-Induced Platelet Aggregation Against
Baseline and Isotype Control Antibodies
Rabbit polyclonal anti-b2GP1 antibodies (1.25 mg/mL) signif-
icantly inhibited %MAX (4.08% + 0.93%, P < .01) and
%AUC (4.71% + 1.22%, P < .01) compared to baseline
control; however, their effects on lag time were the same as
baseline (Figure 1D to F). There was also no significant differ-
ence between the inhibitory effects of rabbit polyclonal anti-
b2GP1 and the isotype control antibodies (Figure 1D to F).
Effects of Rabbit Monoclonal Anti-b2GP1 IgG Antibodies
on 2.5 mg/mL Collagen-Induced Platelet Aggregation
Against Baseline and Isotype Control Antibodies
Rabbit monoclonal anti-b2GP1 antibodies (1.25 mg/mL) did not
show a significant difference compared to baseline; however,
2.5 and 5 mg/mL concentrations of anti-b2GP1 antibodies sig-
nificantly inhibited %MAX (3.57% + 1.27%, P < .01 and
4.56% + 1.27%, P < .01, respectively) and %AUC (5.43%
+ 1.56%, P < .01 and5.91% + 1.56%, P < .01, respectively;
Figure 1G, H). Furthermore, 2.5 mg/mL of rabbit monoclonal
anti-b2GP1 antibodies prolonged the lag time of aggregation
(3.01 + 1.35 seconds, P = .03; Figure 1I). The effect of rabbit
monoclonal anti-b2GP1 antibodies on platelet aggregation
was similar to their corresponding isotype antibodies
(Figure 1G to I).
Effects of Anti-b2GP1 Antibodies on LA Activity of NP
Goat polyclonal, rabbit polyclonal, and rabbit monoclonal
anti-b2GP1 antibodies did not demonstrate the LA activity
(Table 2).
Discussion
This study has demonstrated that the 3 commercially available
anti-b2GP1 antibodies inhibited in vitro collagen-induced (2.5
mg/mL) platelet aggregation, compared to baseline control (4%
to 9% inhibition; %MAX and %AUC). These antibodies, how-
ever, produced similar effects in comparison with the isotype
control antibodies investigated in parallel. Furthermore, the 3
anti-b2GP1 antibodies did not demonstrate the LA activity.
Taken together, these results suggest that the anti-b2GP1 anti-
bodies used in the current study may not be suitable for the in
vitro investigation of mechanisms of diseases where anti-
b2GP1 antibodies are implicated in the pathophysiology, such
as APS and SLE.
To our knowledge, only 2 published studies have previ-
ously investigated the effects of anti-b2GP1 antibodies on
collagen-induced platelet aggregation.3,11 The relatively
small amount of inhibition of aggregation by anti-b2GP1 anti-
bodies compared to baseline demonstrated in the current study
is similar to a previous study that investigated human serum
containing anti-b2GP1 IgG antibodies.
11 However, this is in
contrast to a previous study by our group3 that demonstrated
increasing concentrations of rabbit polyclonal anti-b2GP1
IgG antibodies enhanced collagen-induced platelet aggrega-
tion (%AUC) compared to baseline control. As the changes to
aggregation in the presence of anti-b2GP1 antibodies com-
pared to baseline control are relatively small, this suggests
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that there may be some variability between sources of anti-
bodies, particularly binding strengths and/or specificities.
Furthermore, the very similar effects demonstrated by the
anti-b2GP1 antibodies used in the current study and their
paired isotype controls provide further evidence that these
commercially available anti-b2GP1 antibodies probably do
not have a significant effect on collagen-induced in vitro
platelet aggregation.
Figure 1. Effects of commercially available animal-derived polyclonal and monoclonal IgG antibodies on 2.5 mg/mL collagen-induced platelet
aggregation. Horizontal dotted lines represent the baseline (PRP + buffered normal saline only). For each antibody, results are presented as the
mean difference against baseline + standard error of the mean from 4 separate experiments. All 3 animal-derived anti-human-b2GP1 antibodies
had inhibitory effects compared to baseline control on 2.5 mg/mL collagen-induced platelet aggregation. However, these effects parallel with
their isotype control antibodies. b2GP1 indicates beta-2-glycoprotein 1; IgG, immunoglobulin G; PRP, platelet-rich plasma.
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It was also interesting to observe that none of the 3 com-
mercial anti-b2GP1 antibodies demonstrated the LA activity, as
determined by the dilute Russell viper venom coagulation test.5
This suggests that the antibodies used in the current study had
the characteristics of nonpathological “type B” anti-b2GP1
antibodies, as opposed to “type A” pathological antidomain
(D) I-b2GP1 antibodies that have been implicated in patients
with APS and SLE.15,16 Furthermore, the variable effects of
patient (SLE)-derived anti-b2GP1 and rabbit anti-b2GP1 anti-
bodies are consistent with data from a previous study that
investigated their effects on ADP-induced platelet aggrega-
tion.1 Anti-b2GP1 antibodies purified from 2 patients with SLE
demonstrated the concentration-dependent (1.25 to 10 mg/mL)
increases in platelet aggregation (%MAX, %AUC) in the pres-
ence of 2.5 and 5 mM ADP, compared to the inhibitory effects
of 10 mg/mL rabbit anti-b2GP1.
1
The data presented in this study raise doubt about the suit-
ability of using animal-derived anti-b2GP1 for research studies
into the mechanisms of action of anti-b2GP1 antibodies. The
characteristics of animal-derived anti-b2GP1 antibodies may
vary as they are dependent on the structure of b2GP1 used to
immunize animals. In healthy human plasma, most b2GP1 is
present in a circular conformation.17 Animals immunized with
circular b2GP1 are less likely to generate type A anti-DI-b2GP1
antibodies as the cryptic epitope in DI is hidden by DV.17 This
is in contrast to when the cryptic epitope is/remains exposed
when circular-shaped b2GP1 transforms into the J-shaped con-
formation. Yet, transformation is only favored in b2GP1 with
increased oxidation18 or sialylation of glycan structure,19 nor-
mally found in patients with APS and SLE. Alkaline pH,17 high
salts,17 and b2GP1 concentration
20 also promote transforma-
tion, but these conditions can only be generated in vitro.
Anti-b2GP1 IgG antibody subclasses have varying pathogeni-
cities.21 Anti-b2GP1 IgG2 and IgG3 antibodies are found in
patients with APS and healthy children, respectively. Yet, IgG3
antibodies activate C3c to enhance the clearance of anti-b2GP1–
b2GP1 complexes and protect children from complications.
21,22
Therefore, it is possible that commercially available animal-
derived anti-b2GP1 antibodies are nonpathological type B IgG3
antibodies. The targeted epitope and subclasses of animal-
derived antibodies used in future studies need to be clarified to
better correlate with in vivo pathological manifestations.
Similarly, the source of collagen used to investigate the effects
of anti-b2GP1 antibodies on platelets may affect results. The type
I equine tendon collagen (Helena Laboratories) used in this study
to activate platelets in the presence of anti-b2GP1 antibodies
contained a substantial amount of von Willebrand factor (vWF).23
The presence of vWF in this reagent acts synergistically with
collagen to increase the potency of collagen in supporting platelet
adhesion and aggregation.23 We attempted to use 2 other sources
of collagen (calf skin type I acid soluble collagens, C3511 and
C9791, Sigma-Aldrich, St Louis, Missouri) in the current study,
but neither was able to induce platelet aggregation in a range of
healthy donors (data not shown). Whether the results in the cur-
rent study were due to pathways mediated by vWF, collagen, or
both was therefore unable to be determined.
Finally, it is possible that the PRP-based in vitro aggregation
system used in the study is not suitable to investigate the effects
of anti-b2GP1 antibodies on platelets.
10,24 In vivo, platelets
expose negatively charged phospholipid after adherence to col-
lagen, allowing transformation of circular b2GP1 to J-shaped
and formation of complexes. Using a PRP-based in vitro aggre-
gation system, collagen and platelets in a fluid phase are not
exposed to damaged endothelial cells. Thus, exposure of nega-
tively charged platelet phospholipids only occurs to a minor
extent at the end of the aggregation process.24 The anti-b2GP1–
b2GP1 complexes might not be formed and therefore have no
effect on platelet aggregation. It may be that anti-b2GP1–
b2GP1 complexes only promote platelet interaction with col-
lagen under more physiological flow conditions.25 Moreover,
anti-b2GP1 antibodies may require additional exogenous
b2GP1 to activate platelets.
26
Conclusion
This study demonstrated that the 3 commercially available
animal-derived anti-human-b2GP1 antibodies did not affect
collagen-induced in vitro platelet aggregation, relative to their
respective isotype controls. The antibodies used were probably
nonpathological, type B anti-b2GP1 antibodies as they had no
significant effect on collagen-induced in vitro platelet aggrega-
tion and did not demonstrate LA activity. This study highlights
the importance of using both isotype antibodies and negative
controls in parallel to validate the inhibitory or pro-aggregatory
effects of anti-b2GP1 antibodies. This study has also high-
lighted that caution is required when interpreting the effects
of anti-b2GP1 antibodies on platelets in clinical conditions, as
the effects are dependent on their targeted domain epitope.
Table 2. Lupus Anticoagulant (LA) Activity of Commercially Available






LA control lowc 63.8 + 0.3 46.2 + 0.6 1.4
LA control highd 81.4 + 0.5 42.5 + 0.1 1.9
NP 0 37.6 + 0.2 Normal
Goat polyclonal anti-
b2GP1 IgG + NP
5 37.2 + 0.2 Normal
2.5 37.1 + 0.2 Normal
1.25 37.0 + 0.1 Normal
Rabbit polyclonal anti-
b2GP1 IgG + NP
5 39.1 + 0.5 Normal
2.5 37.5 + 0.0 Normal




5 36.1 + 0.1 Normal
2.5 36.2 + 0.2 Normal
1.25 36.3 + 0.1 Normal
Abbreviations: [Antibody], final concentration of antibodies; anti-b2GP1, anti-
beta-2-glycoprotein 1; C, “confirm” clotting time; IgG, immunoglobulin G; LA,
lupus anticoagulant; NP, STA®-Coag lyophilized control citrated normal human
plasma; S, “screen” clotting time; S/C ratio, screen ratio/confirm ratio.
aResults were expressed as mean + standard deviation from 3 replicates.
bResults were expressed as mean (standard deviation) from 3 replicates.
cLow control S/C reference ratio: 1.35 to 1.65.
dHigh control S/C reference ratio: 1.7 to 2.4.
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Further studies are required to use anti-b2GP1 antibodies with
known targeted epitopes, for example, immunoassays, to mea-
sure anti-DI-b2GP1 antibodies to better correlate in vitro
results with clinical manifestations.
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